Happy New Year everybody. One of my new year’s resolutions is to post more frequently in 2015, and I’m going to start by taking a look at a recently published paper by Susan Snyder and colleagues titled “Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision making in the face of complexity”. This is a review paper that takes a look at the need for, and current use of economic evaluations in pharmacogenomics, identifying both obstacles to progress and also areas where, actually, we’re doing ok at the moment. There have been a few papers covering similar ground in the past couple of years (interested readers should check out Faulkner et al., Annemans et al. and, in a shameless act of self-promotion, one of my publications) and I think all of them have made a significant contribution to the literature in one way or another. Snyder et al. do so as well. Rather than review their paper in full, I wanted to focus on their unique contribution by pulling out a couple of points of interest that might prompt further discussion.

Continue reading →